PortalPublikationenContemporary role of prostate cancer antigen 3 in the manage...

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Standard

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. / Auprich, Marco; Bjartell, Anders; Chun, Felix; de La Taille, Alexandre; Freedland, Stephen J; Haese, Alexander; Schalken, Jack; Stenzl, Arnulf; Tombal, Bertrand; van der Poel, Henk.

in: EUR UROL, Jahrgang 60, Nr. 5, 5, 2011, S. 1045-1054.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Auprich, M, Bjartell, A, Chun, F, de La Taille, A, Freedland, SJ, Haese, A, Schalken, J, Stenzl, A, Tombal, B & van der Poel, H 2011, 'Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.', EUR UROL, Jg. 60, Nr. 5, 5, S. 1045-1054. <http://www.ncbi.nlm.nih.gov/pubmed/21871709?dopt=Citation>

APA

Auprich, M., Bjartell, A., Chun, F., de La Taille, A., Freedland, S. J., Haese, A., Schalken, J., Stenzl, A., Tombal, B., & van der Poel, H. (2011). Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. EUR UROL, 60(5), 1045-1054. [5]. http://www.ncbi.nlm.nih.gov/pubmed/21871709?dopt=Citation

Vancouver

Auprich M, Bjartell A, Chun F, de La Taille A, Freedland SJ, Haese A et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. EUR UROL. 2011;60(5):1045-1054. 5.

Bibtex

@article{55255001fbb54eed805f6a85b420835c,
title = "Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.",
abstract = "Newly discovered biomarkers ideally should prove clinical usefulness, provide additional detection, staging, and prognosis information to improve individual risk assessment, and potentially permit targeted cancer therapy.",
keywords = "Biopsy, Humans, Male, Risk Factors, Predictive Value of Tests, Prognosis, Risk Assessment, Patient Selection, Neoplasm Staging, Evidence-Based Medicine, Decision Support Techniques, Early Detection of Cancer, Antigens, Neoplasm/genetics/*urine, Prostatic Neoplasms/diagnosis/genetics/pathology/therapy/*urine, Tumor Markers, Biological/genetics/*urine, Biopsy, Humans, Male, Risk Factors, Predictive Value of Tests, Prognosis, Risk Assessment, Patient Selection, Neoplasm Staging, Evidence-Based Medicine, Decision Support Techniques, Early Detection of Cancer, Antigens, Neoplasm/genetics/*urine, Prostatic Neoplasms/diagnosis/genetics/pathology/therapy/*urine, Tumor Markers, Biological/genetics/*urine",
author = "Marco Auprich and Anders Bjartell and Felix Chun and {de La Taille}, Alexandre and Freedland, {Stephen J} and Alexander Haese and Jack Schalken and Arnulf Stenzl and Bertrand Tombal and {van der Poel}, Henk",
year = "2011",
language = "English",
volume = "60",
pages = "1045--1054",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

AU - Auprich, Marco

AU - Bjartell, Anders

AU - Chun, Felix

AU - de La Taille, Alexandre

AU - Freedland, Stephen J

AU - Haese, Alexander

AU - Schalken, Jack

AU - Stenzl, Arnulf

AU - Tombal, Bertrand

AU - van der Poel, Henk

PY - 2011

Y1 - 2011

N2 - Newly discovered biomarkers ideally should prove clinical usefulness, provide additional detection, staging, and prognosis information to improve individual risk assessment, and potentially permit targeted cancer therapy.

AB - Newly discovered biomarkers ideally should prove clinical usefulness, provide additional detection, staging, and prognosis information to improve individual risk assessment, and potentially permit targeted cancer therapy.

KW - Biopsy

KW - Humans

KW - Male

KW - Risk Factors

KW - Predictive Value of Tests

KW - Prognosis

KW - Risk Assessment

KW - Patient Selection

KW - Neoplasm Staging

KW - Evidence-Based Medicine

KW - Decision Support Techniques

KW - Early Detection of Cancer

KW - Antigens, Neoplasm/genetics/urine

KW - Prostatic Neoplasms/diagnosis/genetics/pathology/therapy/urine

KW - Tumor Markers, Biological/genetics/urine

KW - Biopsy

KW - Humans

KW - Male

KW - Risk Factors

KW - Predictive Value of Tests

KW - Prognosis

KW - Risk Assessment

KW - Patient Selection

KW - Neoplasm Staging

KW - Evidence-Based Medicine

KW - Decision Support Techniques

KW - Early Detection of Cancer

KW - Antigens, Neoplasm/genetics/urine

KW - Prostatic Neoplasms/diagnosis/genetics/pathology/therapy/urine

KW - Tumor Markers, Biological/genetics/urine

M3 - SCORING: Journal article

VL - 60

SP - 1045

EP - 1054

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 5

M1 - 5

ER -